Business Wire

nShift: Retailers urged to integrate customer data as 84% of execs struggle with data silos

4.9.2024 16:49:00 CEST | Business Wire | Press release

Share

New nShift guide draws attention to untapped data within delivery and post-purchase processes

Disparate data could be causing retailers to miss crucial commercial opportunities as 84% of execs confess that they have felt the effects of “data silos”.1 This is causing them to miss out on crucial data from the delivery process which often sits across different systems and multiple businesses.

In a new report, nShift, the global leader in experience and delivery management (DMXM) is encouraging retailers to make the most of data generated during the delivery and post-purchase experience.

Retailers have increasingly used large data collections to help improve their sales and operations. A new report by nShift, “Creating a data-driven delivery experience” argues that too often, retailers are missing crucial insights from the delivery and post-purchase process. Typically, such data sits in silos across the organization – or with external carrier companies - making it difficult to use effectively.

Sean Sherwin-Smith, post-purchase product director at nShift said: “The delivery process is a fantastic example of where retailers sit upon a wealth of untapped data. Information from the delivery and post-purchase process can shine a real light on how retailers and warehouses can improve efficiency, revamp the customer experience and turn one-off purchases into lifelong customer relationships.

“The problem is that retailers tend to view the fulfillment process and the customer experience as two separate things. As a result, data sits in disjointed systems and is rarely compiled and analyzed. Only by bringing deliveries and experience management together can retailers tap into crucial insights and create data-driven growth strategies.”

The new nShift report explores how leveraging data from the delivery and post-purchase experience can help retailers:

  1. Optimize and reduce carrier costs - the greater access a retailer or warehouse has to carrier costs and performance data, the more easily they can select the most cost-effective last-mile delivery option for each shipment
  2. Improve conversions at checkout – by ensuring that a shopper sees the delivery option they want at the top of the list of choices
  3. Create better customer communications – retailers can then create relevant communications to match how often, according to data, people are checking updates and weave in product plugs or brand messages as appropriate
  4. Increase customer loyalty by keeping their delivery promise – comparing performance data across carrier companies enables retailers to drive up standards and negotiate better results
  5. Retain more revenue by reducing volumes – by paying close attention to what issues are causing people to send products back and addressing such issues with product and marketing teams
  6. Influence consumer behavior – to encourage more shoppers into physical stores or to alter their returns habits

nShift’s DMXM suits of solutions bring together core components of delivery management (such as label printing and carrier booking) with cutting-edge consumer applications. Because delivery management, order tracking, checkout and returns all sit on one platform, it’s easy to join up the relevant data. A range of easy-to-use dashboards makes insights clear, digestible, sharable and actionable.

Read the full report: “Creating a data-driven delivery experience: how delivery and experience management (DMXM) unlocks business-changing insights for online retailers

About nShift

nShift’s delivery & experience management (DMXM) platform drives ecommerce success. Grow beyond limits with constant innovation and the world’s largest carrier network. Build customer loyalty with end-to-end tools that enhance experience. Unify data into usable insight that connects and optimizes processes. With nShift, make delivery the essential link between your brand and your customers.

nShift. Worry less. Ship smarter. www.nshift.com

1https://www.mckinsey.com/capabilities/growth-marketing-and-sales/our-insights/the-value-of-getting-personalization-right-or-wrong-is-multiplying

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904597279/en/

Contacts

James Ellerington: James.Ellerington@fourteenforty.uk / (+44) 07725 534941

James Ellerington: James.Ellerington@fourteenforty.uk / (+44) 07725 534941

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye